Effect of retinoic acid and delta-like 1 homologue (DLK1) on differentiation in neuroblastoma.
The principal objective of this study was to evaluate the chemopreventive and therapeutic effects of a combination of all-trans-retinoic acid (RA) and knockdown of delta-like 1 homologue (Drosophila) (DLK1) on neuroblastoma, the most common malignant disease in children. As unfavorable neuroblastoma is poorly differentiated, neuroblastoma cell was induced differentiation by RA or DLK1 knockdown. Neuroblastoma cells showed elongated neurite growth, a hallmark of neuronal differentiation at various doses of RA, as well as by DLK1 knockdown. In order to determine whether or not a combination of RA and DLK1 knockdown exerts a greater chemotherapeutic effect on neuroblastoma, cells were incubated at 10 nM RA after being transfected with SiRNA-DLK1. Neuronal differentiation was increased more by a combination of RA and DLK1 knockdown than by single treatment. Additionally, in order to assess the signal pathway of neuroblastoma differentiation induced by RA and DLK1 knockdown, treatment with the specific MEK/ERK inhibitors, U0126 and PD 98059, was applied to differentiated neuroblastoma cells. Differentiation induced by RA and DLK1 knockdown increased ERK phosphorylation. The MEK/ERK inhibitor U0126 completely inhibited neuronal differentiation induced by both RA and DLK1 knockdown, whereas PD98059 partially blocked neuronal differentiation. After the withdrawal of inhibitors, cellular differentiation was fully recovered. This study is, to the best of our knowledge, the first to demonstrate that the specific inhibitors of the MEK/ERK pathway, U0126 and PD98059, exert differential effects on the ERK phosphorylation induced by RA or DLK1 knockdown. Based on the observations of this study, it can be concluded that a combination of RA and DLK1 knockdown increases neuronal differentiation for the control of the malignant growth of human neuroblastomas, and also that both MEK1 and MEK2 are required for the differentiation induced by RA and DLK1 knockdown.
Kim
Yuri
Y
Department of Nutritional Science and Food Management, Ewha Womans University, 11-1 Daehyun-dong, Seodaemun-gu, Seoul 120-750, Korea.
Clin Cancer Res. 1996 Mar;2(3):511-20
9816198
Differentiation. 2000 Aug;66(1):49-59
10997592
World J Surg. 2005 Mar;29(3):317-24
15706435
J Biol Chem. 1993 Feb 25;268(6):3817-20
8095043
J Nucl Med. 2004 Jul;45(7):1172-88
15235064
Brain Res. 2009 Feb 23;1256:8-18
19135033
J Biol Chem. 2000 Apr 21;275(16):11915-20
10766819
Methods Mol Biol. 2000;99:161-75
10909084
Mol Cancer Ther. 2007 Apr;6(4):1425-32
17431121
Oncogene. 2005 Jun 23;24(27):4472-6
15806146
Histochem Cell Biol. 1996 Dec;106(6):535-42
8985741
J Clin Oncol. 1999 Jul;17(7):2264-79
10561284
J Immunol. 2000 Jan 1;164(1):256-64
10605019
Int J Cancer. 2003 May 20;105(1):61-9
12672031
Oncogene. 2006 Mar 23;25(13):1852-61
16288219
Cell. 1995 Jan 27;80(2):225-36
7834742
Histol Histopathol. 2000 Jan;15(1):119-29
10668203
Mol Cell Biol. 2005 Apr;25(8):3040-55
15798192
J Biol Chem. 1998 Jul 17;273(29):18623-32
9660836
Leukemia. 2005 Aug;19(8):1404-10
15959531
Lancet Oncol. 2008 Mar;9(3):247-56
18308250
Science. 1965 Aug 20;149(3686):879-80
14332853
Cancer Res. 2009 Dec 15;69(24):9271-80
19934310
Horm Metab Res. 2002 Nov-Dec;34(11-12):664-70
12660879
J Biol Chem. 1995 Nov 17;270(46):27489-94
7499206
Clin Cancer Res. 2001 Oct;7(10):2955-7
11595682
Leukemia. 2000 Aug;14(8):1371-7
10942231
Methods Enzymol. 2001;332:417-31
11305115
Blood. 1999 Aug 15;94(4):1192-200
10438706
Mol Cell Biol. 1998 Sep;18(9):5247-55
9710609
Biochem J. 2000 Oct 1;351(Pt 1):95-105
10998351
Nat Rev Cancer. 2003 Mar;3(3):203-16
12612655
J Cell Biochem. 2004 Jun 1;92(3):525-33
15156564
FEBS Lett. 2004 Feb 27;560(1-3):178-82
14988019
J Neurobiol. 2006 Jun;66(7):606-30
16688755
Genome Biol. 2006;7(9):R84
16989664
Cell. 1993 May 21;73(4):725-34
8500166
J Clin Oncol. 1997 Feb;15(2):790-5
9053506
J Thorac Oncol. 2008 Jun;3(6 Suppl 2):S128-30
18520295